The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Age > or = 18 years
HCC confirmed on imaging, BCLC stage 0, A, B, or C
Transarterial Y90 radioembolization approved by multidisciplinary tumor board -
Not eligible for Y90 procedure
Prior surgery or ablation on indicated tumors
Patient unable to complete the follow up visits required for clinical care or research -